Barrett Conner, MD
Pulmonary Disease · Hermitage, TNNPI 1326046673
Payments from drug & device makers
Across 396 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$994
- GSK$772
- AstraZeneca$594
- Insmed, Inc.$451
- Merck$423
- plus $3K from 35 others
What the payments were for
- Food & beverage$8,03899%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 85 | $1,773 |
| Boehringer Ingelheim | 47 | $994 |
| GSK | 45 | $772 |
| AstraZeneca | 33 | $594 |
| Insmed, Inc. | 23 | $451 |
| Merck | 18 | $423 |
| Regeneron Healthcare Solutions, Inc. | 14 | $366 |
| United Therapeutics Corporation | 12 | $341 |
| Sanofi | 15 | $315 |
| Grifols USA, LLC | 9 | $200 |
| Mylan Specialty L.p. | 9 | $161 |
| Inspire Medical Systems, Inc. | 5 | $150 |
| Baxter Healthcare | 7 | $129 |
| Harmony Biosciences LLC | 5 | $122 |
| Philips North America LLC | 6 | $121 |
| Bayer | 6 | $107 |
| Novartis | 7 | $100 |
| Pfizer | 5 | $92 |
| Intuitive Surgical | 1 | $91 |
| Amgen | 4 | $73 |
| Portola Pharmaceuticals, LLC | 4 | $69 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $67 |
| Johnson & Johnson(2 entities) | 2 | $60 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| Electromed, Inc. | 3 | $48 |
| Viatris Specialty LLC | 2 | $44 |
| Paratek Pharmaceuticals, Inc. | 3 | $41 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Verona Pharma, Inc. | 2 | $39 |
| Genentech USA, Inc. | 3 | $38 |
| Lilly USA, LLC | 2 | $30 |
| Pulmonx Corporation | 1 | $28 |
| Ambu Inc. | 1 | $26 |
| Advanced Respiratory, Inc | 2 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| ZOLL Respicardia, Inc. | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $21 |
| Vapotherm Inc | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Circassia Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,106 in reported general payments places this provider in the 65th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 17 | $347,707 |
| OpsumitMacitentan | 25 | $299,602 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 249 | $206,343 |
| AdempasRiociguat | 12 | $159,362 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 66 | $41,815 |
| EliquisApixaban | 55 | $35,559 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $32,714 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $28,765 |
| Spiriva RespimatTiotropium Bromide | 22 | $19,051 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $12,214 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $9,851 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $7,801 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 202 | $6,410 |
| Arnuity ElliptaFluticasone Furoate | 20 | $6,204 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $4,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,773 | $647,30942 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $772 | $287,075405 claims |
| BayerAdempas | $107 | $159,36212 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $994 | $39,06654 claims |
| PfizerEliquis | $92 | $35,55955 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $594 | $32,92155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Hermitage
- Anand PopuriHermitage$22K
- Fabien MaldonadoNashville$2.5M
- Aaron MilstoneFranklin$2.4M
- John SwisherKnoxville$2.3M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Clyde SouthwellHendersonville$801K
- Krishnendu BhadraChattanooga$631K
- Eric WeaverKnoxville$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.